| 1. |
- Carlstedt-Duke, J
(författare)
-
Glucocorticoid Receptor beta: View II
- 1999
-
Ingår i: Trends in endocrinology and metabolism: TEM. - : Elsevier BV. - 1879-3061 .- 1043-2760. ; 10:8, s. 339-342
-
Tidskriftsartikel (refereegranskat)
|
|
| 2. |
|
|
| 3. |
- Alexandraki, Krystallenia I., et al.
(författare)
-
Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
- 2020
-
Ingår i: Trends in endocrinology and metabolism. - : Elsevier. - 1043-2760 .- 1879-3061. ; 31:3, s. 239-255
-
Tidskriftsartikel (refereegranskat)abstract
- Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are increasingly recognized, characterized by prolonged survival even with metastatic disease. Their medical treatment is complex involving various specialties, necessitating awareness of treatment-related adverse effects (AEs). As GEP-NENs express somatostatin receptors (SSTRs), long-acting somatostatin analogs (SSAs) that are used for secretory syndrome and tumor control may lead to altered glucose metabolism. Everolimus and sunitinib are molecular targeted agents that affect glucose and lipid metabolism and may induce hypothyroidism or hypocalcemia, respectively. Chemotherapeutic drugs can affect the reproductive system and water homeostasis, whereas immunotherapeutic agents can cause hypophysitis and thyroiditis or other immune-mediated disorders. Treatment with radiopeptides may temporarily lead to radiation-induced hormone disturbances. As drugs targeting GEP-NENs are increasingly introduced, recognition and management of endocrine-related AEs may improve compliance and the quality of life of these patients.
|
|
| 4. |
|
|
| 5. |
- Balgoma, David, et al.
(författare)
-
Common Fatty Markers in Diseases with Dysregulated Lipogenesis
- 2019
-
Ingår i: Trends in endocrinology and metabolism. - : ELSEVIER SCIENCE LONDON. - 1043-2760 .- 1879-3061. ; 30:5, s. 283-285
-
Tidskriftsartikel (refereegranskat)abstract
- Recent studies have reported the upregulation of a subgroup of triacylglycerides as markers of different diseases with dysregulated lipogenesis, which means that these markers are not selective. This observation has a deep impact on their use as diagnostic tools in clinical practice (e.g., markers of risk of type 2 diabetes).
|
|
| 6. |
- Balgoma, David, et al.
(författare)
-
Etherglycerophospholipids and ferroptosis : structure, regulation, and location
- 2021
-
Ingår i: Trends in endocrinology and metabolism. - : Elsevier. - 1043-2760 .- 1879-3061. ; 32:12, s. 960-962
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Two pioneering studies by Zou et al. and Cui et al. have reported that the synthesis of etherglycerophospholipids (etherPLs) sensitizes cells to ferroptosis. The location and regulation of etherPLs suggest that: (i) lipid peroxidation in the inner leaflet of the plasma membrane might be of importance in ferroptosis, and (ii) different etherPLs may differently sensitize cells to ferroptosis.
|
|
| 7. |
|
|
| 8. |
- Cannon, Barbara, et al.
(författare)
-
A PERKy way to make mitochondrial cristae
- 2021
-
Ingår i: Trends in endocrinology and metabolism. - : Elsevier BV. - 1043-2760 .- 1879-3061. ; 32:7, s. 417-419
-
Forskningsöversikt (refereegranskat)abstract
- PERK protein, that is canonically associated with the response to endoplasmic reticulum stress, may be acquiring a new role as a regulator of the growth of mitochondrial cristae. This role is pertinent not only to the recruitment of brown adipose tissue thermogenic capacity but probably also to directing cristae formation in highly metabolically active organs such as the heart.
|
|
| 9. |
- Cao, Yihai
(författare)
-
Erythropoietin in cancer: a dilemma in risk therapy
- 2013
-
Ingår i: Trends in endocrinology and metabolism. - : Elsevier. - 1043-2760 .- 1879-3061. ; 24:4, s. 190-199
-
Forskningsöversikt (refereegranskat)abstract
- Erythropoietin (EPO) is a frequently prescribed drug for treatment of cancer-related and chemotherapy-induced anemia in cancer patients. Paradoxically, recent preclinical and clinical studies indicate that EPO could potentially accelerate tumor growth and jeopardize survival in cancer patients. In this review I critically discuss the current knowledge and broad biological functions of EPO in association with tumor growth, invasion, and angiogenesis. The emphasis is focused on discussing the complex interplay between EPO and other tumor-derived factors in angiogenesis, tumor growth, invasion, and metastasis. Understanding the multifarious functions of EPO and its reciprocal relation with other signaling pathways is crucial for developing more effective agents for cancer therapy and for minimizing risks for cancer patients.
|
|
| 10. |
|
|
